WO2010138661A8 - Compositions anticancéreuses nanoparticulaires et procédés de production de celles-ci - Google Patents

Compositions anticancéreuses nanoparticulaires et procédés de production de celles-ci Download PDF

Info

Publication number
WO2010138661A8
WO2010138661A8 PCT/US2010/036304 US2010036304W WO2010138661A8 WO 2010138661 A8 WO2010138661 A8 WO 2010138661A8 US 2010036304 W US2010036304 W US 2010036304W WO 2010138661 A8 WO2010138661 A8 WO 2010138661A8
Authority
WO
WIPO (PCT)
Prior art keywords
making
methods
nanoparticulate
same
anticancer compositions
Prior art date
Application number
PCT/US2010/036304
Other languages
English (en)
Other versions
WO2010138661A1 (fr
Inventor
David Slifer
Janine Keller
Original Assignee
Elan Pharma International Ltd.
Sanofi Aventis
Mcgurk, Simon, L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd., Sanofi Aventis, Mcgurk, Simon, L. filed Critical Elan Pharma International Ltd.
Publication of WO2010138661A1 publication Critical patent/WO2010138661A1/fr
Publication of WO2010138661A8 publication Critical patent/WO2010138661A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des formulations injectables de 3-(2,4-dichloro-phényl)-l,6-diméthyl-l,9-dihydro-pyrido[2,3-b]indol-2-one particulaire qui possèdent une durée d'action prolongée lors de leur administration, et des procédés de production et d'utilisation de ces formulations. Lesdites formulations injectables comprennent du 3-(2,4-dichloro-phényl)-l,6-diméthyl-l,9-dihydro-pyrido[2,3-b]indol-2-one particulaire.
PCT/US2010/036304 2009-05-27 2010-05-27 Compositions anticancéreuses nanoparticulaires et procédés de production de celles-ci WO2010138661A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18163809P 2009-05-27 2009-05-27
US61/181,638 2009-05-27
FR1002210 2010-05-26
FR1002210A FR2945950A1 (fr) 2009-05-27 2010-05-26 Compositions de nanoparticules anticancereuses et procedes pour les preparer

Publications (2)

Publication Number Publication Date
WO2010138661A1 WO2010138661A1 (fr) 2010-12-02
WO2010138661A8 true WO2010138661A8 (fr) 2011-01-27

Family

ID=43088123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/036304 WO2010138661A1 (fr) 2009-05-27 2010-05-27 Compositions anticancéreuses nanoparticulaires et procédés de production de celles-ci

Country Status (2)

Country Link
FR (1) FR2945950A1 (fr)
WO (1) WO2010138661A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659156A (zh) * 2014-04-30 2017-05-10 科莱恩国际有限公司 促进土壤增湿和植物生长的表面活性剂浓缩物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2854751B1 (fr) 2012-05-30 2016-08-10 Clariant International Ltd. Utilisation de n-méthyl-n-acylglucamines comme solubilisants
WO2013178679A2 (fr) 2012-05-30 2013-12-05 Clariant International Ltd. Composition contenant de la n-méthyl-n-acylglucamine
DE102012021647A1 (de) 2012-11-03 2014-05-08 Clariant International Ltd. Wässrige Adjuvant-Zusammensetzungen
RS61536B1 (sr) 2014-03-26 2021-04-29 Astex Therapeutics Ltd Kombinacije fgfr- i cmet-inhibitora za lečenje kancera
DE102014005771A1 (de) 2014-04-23 2015-10-29 Clariant International Ltd. Verwendung von wässrigen driftreduzierenden Zusammensetzungen
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
EP3101085A1 (fr) 2015-06-01 2016-12-07 Cytec Industries Inc. Compositions de tensioactifs moussants
DE102015219608B4 (de) 2015-10-09 2018-05-03 Clariant International Ltd Universelle Pigmentdispersionen auf Basis von N-Alkylglukaminen
DE102015219651A1 (de) 2015-10-09 2017-04-13 Clariant International Ltd. Zusammensetzungen enthaltend Zuckeramin und Fettsäure
DE202016003070U1 (de) 2016-05-09 2016-06-07 Clariant International Ltd. Stabilisatoren für Silikatfarben
CN107056620A (zh) * 2017-05-05 2017-08-18 如皋市万利化工有限责任公司 混合季铵盐的生产工艺
JP7214879B2 (ja) * 2019-02-01 2023-01-30 メッドシャイン ディスカバリー インコーポレイテッド ｃ－Ｍｅｔ阻害剤としてのピリミジニルを含むトリシクリル系化合物
CN113329276B (zh) * 2020-02-28 2022-10-28 华为技术有限公司 数据传输方法、装置、网关、芯片及存储介质
WO2022022687A1 (fr) * 2020-07-31 2022-02-03 南京明德新药研发有限公司 Formes salines et cristallines d'un composé tricyclique contenant un groupe pyrimidine et leur procédé de préparation

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403078A1 (fr) 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
DE8703104U1 (de) 1987-02-28 1987-04-16 Heeg, Otto, 6450 Hanau Möbelfrontelement
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU2317592A (en) 1991-07-05 1993-02-11 University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5264610A (en) 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5525328A (en) 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5466440A (en) 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5500204A (en) 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
DE69633222T2 (de) 1995-02-24 2005-09-08 Elan Pharma International Ltd. Nanopartikel-dispersionen enthaltende aerosole
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5643552A (en) 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
WO1998035666A1 (fr) 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6431478B1 (en) 1999-06-01 2002-08-13 Elan Pharma International Limited Small-scale mill and method thereof
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659156A (zh) * 2014-04-30 2017-05-10 科莱恩国际有限公司 促进土壤增湿和植物生长的表面活性剂浓缩物
CN106659156B (zh) * 2014-04-30 2019-09-10 科莱恩国际有限公司 促进土壤增湿和植物生长的表面活性剂浓缩物

Also Published As

Publication number Publication date
FR2945950A1 (fr) 2010-12-03
WO2010138661A1 (fr) 2010-12-02

Similar Documents

Publication Publication Date Title
WO2010138661A8 (fr) Compositions anticancéreuses nanoparticulaires et procédés de production de celles-ci
WO2011057225A3 (fr) Particules auto-assemblées de polymères zwitterioniques et procédés associés
WO2006055603A3 (fr) Formulations injectables de nanoparticules d'olanzapine
IL220571A (en) Compounds of 3 - (3-phenyl-imidazo [5,4- b] pyridinyl) -2-conjugated aminopyridine and pharmaceutical preparations containing them
WO2010054266A3 (fr) Copolymères multiséquencés
WO2010037054A3 (fr) Antagonistes hétéroaryliques des récepteurs de prostaglandine d<sb>2</sb>
WO2010003127A3 (fr) Antagonistes des récepteurs de la prostaglandine d<sb>2</sb>
WO2011142858A3 (fr) Variants de la chlorotoxine, conjugués, et leurs méthodes d'utilisation
WO2010008864A3 (fr) Antagonistes de cycloalcane[b]indole de récepteurs de prostaglandine d2
WO2010057118A3 (fr) Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
WO2012021415A3 (fr) Compositions buccales comprenant un composé de zinc et un agent antimicrobien
HK1164292A1 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
WO2010009127A3 (fr) Compositions de blanchiment des dents et procédés
WO2009140642A3 (fr) Antagonistes tricycliques de récepteurs de prostaglandine d<sb>2</sb>
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2005112633A3 (fr) Composes et compositions pour administration d’agents actifs
WO2010039977A3 (fr) Antagonistes d'hétéroaryle des récepteurs de la prostaglandine d2
IL220432A (en) History of theo [b – 3,2] pyridinedione and pharmaceutical preparations containing them
WO2011079167A3 (fr) Compositions de soin de la bouche
WO2011017502A3 (fr) Formulations comprenant du linaclotide
WO2010021607A3 (fr) Préparation pharmaceutique
WO2011108826A3 (fr) Formulation complexe pour administration orale comprenant une formulation probiotique et un agoniste du récepteur 5-ht4, et procédé de préparation associé
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
WO2009039157A3 (fr) Formulations pharmaceutiques d'orlistat
IL213255A0 (en) Process for the preparation of random radical copolymers, and active substance compositions obtainable therefrom

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10730615

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 10730615

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE